# ALNYLAM PHARMACEUTICALS, INC. (ALNY) · Edgar & Edgarette company card

> Alnylam Pharmaceuticals (ALNY) grew revenue 65.2% in FY2025 to $3.7 billion, operating margin 13.5% against a -3.8% median for pharmaceutical preparations, equity 15.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1178670 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ALNY) · [JSON](https://www.pops4.com/boards/company/ALNY.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $3.7B |
| Revenue growth, 1 year | 65.2% |
| Revenue growth per year | 44.8% |
| Operating margin | 13.5% (prior year -7.9%) |
| Net margin | 8.4% |
| Operating cash flow | $524M |
| Capital spending | $59M |
| Free cash flow | $465M |
| Cash | $1.7B |
| Long-term debt | — |
| Total assets | $5.0B |
| Total equity | $789M |
| Equity ÷ assets | 15.9% |
| Return on equity | 39.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -0.11 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: -1.98 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $3.7B (FY2025). Experience: revenue up 65.2% on the year, up 44.8% a year over 4 years; operating margin 13.5%, up from -7.9%. Soundness: equity 15.9% of assets, return on equity 39.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $4.6B and $7.2B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $3.9B to $8.5B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 13.5% against a -3.8% median; growth 65.2% against 13.7%.

Range logged 2026-11-01, receipt 252aaf22d646b699, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-11-05 ([filing](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000080/0001178670-26-000080-index.htm))

## Recent filings

- 8-K · filed 2026-11-05 · 5.02 Departure or Election of Directors; Appointment of Officers; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000080/0001178670-26-000080-index.htm)
- 10-Q · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000076/0001178670-26-000076-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/0001178670-26-000074-index.htm)
- 10-Q · filed 2026-07-30 · [filing](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/0001178670-26-000062-index.htm)
- 8-K · filed 2026-07-30 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/0001178670-26-000060-index.htm)
- 8-K · filed 2026-05-27 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001178670.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1178670

## Cite

POPS4, Edgar & Edgarette: ALNYLAM PHARMACEUTICALS, INC. (ALNY) company card, from the company's own SEC filings, accessed 2026-11-06, https://www.pops4.com/boards/company/ALNY. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.